Galera Ther­a­peu­tics to cut 70% of staff in wake of re­jec­tion for ra­dio­ther­a­py com­pli­ca­tion treat­ment

Galera Ther­a­peu­tics is chop­ping 70% of its staff in the wake of a sting­ing FDA re­jec­tion for its ex­per­i­men­tal treat­ment for a ra­dio­ther­a­py com­pli­ca­tion that caus­es dif­fi­cul­ties eat­ing and drink­ing.

The FDA late Wednes­day re­ject­ed Galera’s ava­sopasem man­ganese, or ava­sopasem, for the treat­ment of head and neck can­cer pa­tients with ra­dio­ther­a­py-in­duced se­vere oral mu­cosi­tis (SOM), which can oc­cur af­ter re­ceiv­ing ra­di­a­tion and some­times re­quires pa­tients to be on feed­ing tubes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER